NEW YORK – Boston Children's Hospital has granted a worldwide license for an investigational gene therapy for sickle cell disease and beta thalassemia to Caring Cross, the nonprofit announced this ...

Inovio Pharmaceuticals faces an October 30 PDUFA date for INO-3107 with high regulatory risk and only a 5-7 month cash runway. Read why INO stock is a hold.

In Regents of the University of California v. Broad Institute, Inc., the Federal Circuit addressed the issue of conception and reduction to ...

Explore RNA interference methods, comparing siRNA and shRNA for gene knockdown, their mechanisms, advantages, and ...

Published, peer-reviewed research shows a patent-pending, virus-mimicking platform technology developed at Purdue University ...

Krystal Biotech is upgraded to Strong Buy as Vyjuvek sales surge and catalysts build. Click here to know more.

Research about LENN -- a patent-pending, virus-mimicking platform technology that targets bladder cancer cells with mRNA ...

About the LUCE-1 Trial LUCE-1 is a Phase 1/2 multicenter, open-label, dose escalation study investigating safety, tolerability and preliminary efficacy of 3 dose levels of dual AAV8.MYO7A (AAVB-081) ...

AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, recently announced that the United States Food and Drug Administration (FDA) has ...

Sherry Gu, Executive Vice President and CTO at WuXi Biologics, explains the critical challenges of developing bispecific ...

Social media has long been a valuable source of personally identifiable information (PII) for cybercriminals, but the rise of ...

LX2020 generally well tolerated across ten participants with no clinically significant complement activation LX2020 transduction, transcription, ...